Akademik Veri Yönetim Sistemi
The 3rd Immuno-Oncology World Congress, Kobenhavn, Danimarka, 2 - 03 Kasım 2022, ss.43-44
Background: It is important to know the prognostic factors in cancer patients receiving immunotherapy.
Objective: In this study, we aimed to show the effect of prognostic nutritional index (PNI) on survival in patients receiving immune checkpoint inhibitors.
Methods: 117 patients who received immune checkpoint inhibitor (ICI) therapy in the Oncology Department of Çukurova University between 2010 and 2022 were included in the study.
Results: The patients’ 75.2% are male and 24.8% female. The median age of the patients was 59 years. Diagnostic distribution of the patients included in our study, 34 malignant melanoma, 32 lung cancer, 11 renal cell carcinoma, 9 hepatocellular carcinoma, 9 hodgkin lymphoma, 6 mesothelioma, 5 nonhodgkin lymphoma, 3 bladder cancer, 2 head and neck tumor and 1 gastric cancer, 1 testicular cancer, 1 prostate cancer, 1 osteosarcoma, 1 colon cancer, and 1 Kaposi`s sarcoma. The distribution of immune checkpoint inhibitor used in the patients included in our study was nivolumab in 83 patients, pembrolizumab in 14 patients, atezolizumab in 9 patients, ipilimumab in 7 patients, and nivolumab-ipilimumab in 4 patients. Of the patients followed, 50 were alive and 67 were dead. 117 patients were studied. It was found that the area under the curve of the PNI was important in predicting the exitus status at the end of 1 year and the optimum cut-off value was 42.75(sensitivity 55%, specificity 75%). Patients with a PNI at admission 42.75 had a 3.53-fold increased risk of death.
Conclusion: PNI is an important prognostic and predictive marker for mortality in patients using ICI.